Cello Group (LON:CLL)‘s stock had its “buy” rating reaffirmed by analysts at FinnCap in a research report issued to clients and investors on Monday, December 4th. They presently have a GBX 135 ($1.81) target price on the stock. FinnCap’s price objective would suggest a potential upside of 0.75% from the company’s previous close.
Separately, N+1 Singer reaffirmed a “buy” rating and set a GBX 131 ($1.75) target price on shares of Cello Group in a report on Wednesday, September 20th.
Shares of Cello Group (LON CLL) remained flat at $GBX 134 ($1.79) during trading on Monday. Cello Group has a fifty-two week low of GBX 95.20 ($1.27) and a fifty-two week high of GBX 140 ($1.87).
COPYRIGHT VIOLATION WARNING: “FinnCap Reiterates “Buy” Rating for Cello Group (CLL)” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/25/finncap-reiterates-buy-rating-for-cello-group-cll-2.html.
About Cello Group
Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients.
Receive News & Ratings for Cello Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Group and related companies with MarketBeat.com's FREE daily email newsletter.